Celyad Oncology SA (EBR:CYAD)

Belgium · Delayed Price · Currency is EUR

0.390

+0.005 (1.30%)

Feb 27, 2026, 5:35 PM CET

-26.69% (1Y)

Market Cap	17.46M
Revenue (ttm)	186.00K
Net Income (ttm)	-6.46M
Shares Out	44.76M
EPS (ttm)	-0.16
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	56,725
Average Volume	278,470
Open	0.385
Previous Close	0.385
Day's Range	0.380 - 0.410
52-Week Range	0.160 - 0.650
Beta	0.72
RSI	58.92
Earnings Date	Apr 2, 2026

About Celyad Oncology

Celyad Oncology SA, a biotechnology company, focuses on the research and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through Immuno-Oncology and Cardiology segments. The company develops short hairpin ribonucleic acid (shRNA) non-gene-edited technology, which allows for the development of allogenic CAR T-cells through the modulation of genes encoding the T-cell receptor (TCR) without the need for gene editing; NKG2D-based CAR T-cells and multi-specific CAR T-cell platform; and B7-H6 targeting CAR T-... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 19

Stock Exchange Euronext Brussels

Ticker Symbol CYAD

Full Company Profile

Financial Performance

In 2024, Celyad Oncology's revenue was 186,000, an increase of 82.35% compared to the previous year's 102,000. Losses were -5.82 million, -31.06% less than in 2023.

Financial Statements

News

There is no news available yet.